Semaglutide (CAS 910463-68-2) is a high-purity GLP-1 receptor agonist peptide API, a long-acting synthetic analog of human glucagon-like peptide-1 (GLP-1). With a precise 30-amino acid sequence, it mimics the physiological effects of endogenous GLP-1, including glucose-dependent insulin secretion, inhibition of glucagon secretion, and delayed gastric emptying. This dual mechanism of action leads to significant improvements in glycemic control and weight management.
Produced under strict GMP standards, this API ensures consistent purity (≥98%) and biological activity, making it ideal for pharmaceutical formulation. It is widely applied in the development of drugs for the treatment of type 2 diabetes mellitus and obesity, catering to the needs of pharmaceutical manufacturers and research institutions in the field of endocrinology and metabolic diseases.
Its unique ability to provide both glycemic and weight benefits makes it a breakthrough therapy for patients with both diabetes and obesity. Semaglutide delivers reliable therapeutic benefits with a favorable safety profile, supporting the development of effective treatments for metabolic disorders.
